IL2 and metastatic melanoma: The phase-I/II trials with NKTR-214, a pegylated interleukin-2 (IL-2) showing an enhanced response rate on top of nivolumab in several solid tumor types with expanded TILs, have attracted much attention and many doubts [48], while the phase-III trial is ongoing with metastatic melanoma.